Please assess the completion status of the following clinical trial:

Trial Title: Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Admitted to the intensive care unit~* Positive COVID-19 PCR~* Mechanical Ventilation for ≤ 48 hours~* PaO2/FiO2 ≤300~Exclusion Criteria:~* Heparin allergy~* Active bleeding~* Death or withdraw of care anticipated by intensivist within 24 hours~* Platelets\< 50,000 cells/µL~* Clinically significant coagulopathy, as decided by the intensivist~* O2 dependent at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebulized Heparin (Type: EXPERIMENTAL): Heparin 5,000 units/mL Dose: 25,000 units Frequency: every 6 hours Duration: 10 days
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride Dose: 5 mL Frequency: every 6 hours Duration: 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).